The β-carboline derivative Carbacetam attenuates mortality and neuroendocrine dysfunction in a rodent model of traumatic brain injury: A multi-target pharmacological and molecular docking study.
Carbacetam shows promise in reducing mortality and improving recovery in a rodent TBI model, but human studies are needed to confirm its clinical relevance.
Where it sits
this study against the rest of the vasopressin corpusSummary and findings
The study evaluated Carbacetam, a β-carboline derivative, in a rodent model of traumatic brain injury. 125 male Wistar rats received 5 mg/kg/day Carbacetam intraperitoneally for 10 days. Carbacetam significantly reduced mortality and improved neurohumoral and behavioral outcomes.
Abstract
Carbacetam is a synthetic β-carboline with clinical neuroprotective potential whose primary targets include quinone reductase 2 (QR2), neuronal L-type calcium channels (Cav1.2), DYRK1A kinase, and the GABA-A receptor. To evaluate whether this polypharmacological profile provides a mechanistic basis for its efficacy, a two-arm study using a standardised weight-drop moderate traumatic brain injury (TBI) model was conducted in 125 male Wistar rats. Subjects received intraperitoneal Carbacetam (5 mg/kg/day) for 10 days, followed by longitudinal assessments of spatial behaviour, neurohumoral dynamics (hypothalamic-pituitary-adrenal, somatotropic, and vasopressinergic axes), neurological deficits, mortality, and predictive molecular docking. Carbacetam significantly attenuated post-traumatic mortality, yielding a 30-day survival probability of 81.2% compared to 33.2% in untreated TBI controls (log-rank χ<sup>2</sup>(1) = 15.23, p = 9.51 × 10<sup>-5</sup>; Cox proportional-hazards ratio = 0.23, 95% CI 0.10-0.51), corresponding to a 3.55-fold reduction in cumulative 30-day mortality incidence (66.8% vs 18.8%). Behaviourally, the treatment reduced early post-traumatic freezing by 39% and increased mobility by 57% at day 7, with subjects converging toward a non-injured behavioural phenotype by day 45. Treatment significantly accelerated the recovery of reflexive capacity by day 7 (p = 0.003). Neurohumorally, acute post-traumatic hypercortisolism was heavily suppressed (p = 0.008); growth hormone and vasopressin concentrations among surviving Carbacetam-treated animals remained comparable to non-injured reference values through day 30. In silico docking predicted that Carbacetam exhibits nanomolar-range QR2 binding affinity via extensive π-π stacking with the FAD cofactor, alongside predicted secondary structural engagements at the Cav1.2 dihydropyridine site, the canonical DYRK1A hinge-region, and the transmembrane GABA-A neurosteroid pocket. This study provides converging behavioural, neuroendocrine, and computational evidence that Carbacetam exerts neuroprotective effects in experimental TBI consistent with a concentration-dependent, multi-target ligand profile, offering a theoretical structural-to-physiological rationale, pending direct mechanistic validation, for its re-evaluation in neurotraumatology.
Background
Traumatic brain injury (TBI) is a significant cause of mortality and morbidity, with limited effective treatments available. This study investigates Carbacetam, a β-carboline derivative with potential neuroprotective properties, targeting multiple pathways including QR2, Cav1.2, DYRK1A, and GABA-A receptors. Understanding its efficacy in a TBI model could inform future therapeutic strategies.
Methods
The study employed a standardized weight-drop model of moderate TBI in 125 male Wistar rats. Carbacetam was administered intraperitoneally at 5 mg/kg/day for 10 days. Outcomes included mortality, spatial behavior, neurohumoral dynamics, and neurological deficits, alongside molecular docking predictions.
Results
Carbacetam treatment resulted in a 30-day survival probability of 81.2% compared to 33.2% in untreated controls, with a Cox proportional-hazards ratio of 0.23 (95% CI 0.10-0.51). Mortality incidence was reduced by 3.55-fold. Behavioral assessments showed a 39% reduction in freezing and a 57% increase in mobility by day 7. Neurohumoral analysis indicated suppression of acute hypercortisolism (p = 0.008) and maintenance of growth hormone and vasopressin levels comparable to non-injured references.
Interpretation
The findings suggest Carbacetam has a significant impact on survival and neurobehavioral recovery in a rodent TBI model, with a multi-target mechanism of action. While statistically significant, the clinical relevance in humans remains uncertain due to the preclinical nature of the study. The results warrant further investigation, particularly in human trials, to confirm clinical applicability.
Key findings
- 30-day survival probability of 81.2% with Carbacetam vs 33.2% in controls.
- Cox proportional-hazards ratio = 0.23, 95% CI 0.10-0.51.
- 66.8% vs 18.8% cumulative 30-day mortality incidence.
- 39% reduction in early post-traumatic freezing at day 7.
- Acute post-traumatic hypercortisolism suppressed (p = 0.008).
Limitations
- rodent only, no human data
- short 10-day treatment duration
- mechanistic validation pending
- single-species study